Before quadriparesis with dysphagia can be attributed to COVID-19, all differential causes must be excluded
  • Josef Finsterer
    Neurology Department, Neurology & Neurophysiology Centre, Vienna, Austria
  • Sounira Mehri
    Biochemistry Laboratory, LR12ES05 “Nutrition-Functional Foods and Vascular Health”, Faculty of Medicine, Monastir, Tunisia

Keywords

SARS-CoV-2 infection, dysphagia, botulinum toxin, quadruparesis, critically ill myopathy

VIEW THE ENTIRE ARTICLE

References

  • Canta R, Vestito L, Castellini P, Trompetto C, Mori L, De Giovanni A, et al. Successful treatment of post COVID-19 neurogenic dysphagia with botulinum toxin. Eur J Case Rep Intern Med 2023;10:004105.
  • Schefold JC, Wollersheim T, Grunow JJ, Luedi MM, Z'Graggen WJ, Weber-Carstens S. Muscular weakness and muscle wasting in the critically ill. J Cachexia Sarcopenia Muscle 2020;11:1399–1412.
  • Finsterer J, Scorza FA. Guillain-Barre syndrome in 220 patients with COVID-19. Egypt J Neurol Psychiatr Neurosurg 2021;57:55.
  • Sonneville R, Dangayach NS, Newcombe V. Neurological complications of critically ill COVID-19 patients. Curr Opin Crit Care 2023;29:61–67.
  • Views: 124
    HTML downloads: 12
    PDF downloads: 65


    Published: 2024-01-17
    Issue: 2024: Vol 11 No 2 (view)


    How to cite:
    1.
    Finsterer J, Mehri S. Before quadriparesis with dysphagia can be attributed to COVID-19, all differential causes must be excluded. EJCRIM 2024;11 doi:10.12890/2024_004279.